Research News and Research

RSS

Effective treatment for brain cancer in daffodils

When looking for new ways to treat aggressive brain cancers, an international team of scientists turned a new leaf and "discovered" the lowly daffodil. A new research study published in the November 2010 print issue of The FASEB Journal (http://www.fasebj.org) offers hope that a natural compound found in daffodil bulbs, called narciclasine, may be a powerful therapeutic against biologically aggressive forms of human brain cancers.

2 Nov 2010

Vacuum cleaner with UV technology effective at reducing carpet's surface microbes

New research suggests that the addition of ultraviolet light to the brushing and suction of a vacuum cleaner can almost double the removal of potentially infectious microorganisms from a carpet's surface when compared to vacuuming alone.

2 Nov 2010

SRA receives five-year contract to support NTP, NIEHS programmatic initiatives

SRA International, Inc., a leading provider of technology, research, and strategic consulting services and solutions to government organizations and commercial clients, today announced that the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH) awarded the company a contract for up to five years to provide statistical, mathematical, bioinformatic, and computational expertise and support for the National Toxicology Program (NTP) and other NIEHS programmatic initiatives. The contract has a potential total dollar value of $15.5 million.

2 Nov 2010

Provident launches Principals Fund I with $25 million of committed capital

Provident Healthcare Ventures, LLC is pleased to announce the launch of its inaugural Principals Fund I with $25 million of committed capital. All capital invested in the Fund will be provided by the principals of Provident, affirming their belief that providing early-stage healthcare services companies with crucial resources, such as capital and operating expertise, will significantly increase enterprise value over the life of the investment.

2 Nov 2010

NSAIDs drugs prevent colon cancer: Research

Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer by triggering diseased stem cells to self-destruct, according to researchers at the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine.

2 Nov 2010

$Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients$

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

2 Nov 2010

Vitrolife operating income increases 3% to SEK 25 million for January to September 2010

Vitrolife: Growth in local currency was 13 percent. Sales amounted to SEK 217 (207) million, corresponding to an increase of 4 percent in SEK. Operating income before research and development costs increased by 11 percent and amounted to SEK 58 (53) million.

2 Nov 2010

Innovative lifesaving device for patients with advanced heart failure

Bradley Cantley, 41, headed home from UC San Diego Medical Center connected to a lifesaving heart machine called a left ventricular assisted device (LVAD). For patients with advanced heart failure, the mechanical pump rapidly improves circulation throughout the body and serves as a bridge to transplant. Cantley is the first of many patients, locally and globally, who will benefit from the expanded heart surgery program at UC San Diego Health System.

2 Nov 2010

FDA selects Rochester to lead initiative to identify improved pain treatments

Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications - opioids and non-steroidal anti-inflammatory drugs (NSAIDS) - have major drawbacks, including the potential for misuse and abuse and adverse effects that limit long-term use. While scientists have made great strides in understanding the physical and chemical processes that occur when people feel pain, new treatments with improved safety and effectiveness are still needed for the more than 76 million Americans with acute and chronic pain.

2 Nov 2010

Experts discuss latest advancements in gynecological diseases at 2nd China Research Forum

DK Sinopharma, Inc. successfully co-hosted the 2nd China Western Gynecological Diseases Research Forum along with China Physician Association Gynecology Branch and Shaanxi Pharmacology Academic Council. Many experts and scholars in gynecology attended the conference, including 146 gynecologists from large hospitals across China.

2 Nov 2010

Older adults are three times as likely to die following ground-level fall

While simple falls, such as slipping while walking off a curb, may seem relatively harmless, they can actually lead to severe injury and death in elderly individuals, according to a new study published in The Journal of Trauma: Injury, Infection, and Critical Care.

2 Nov 2010

Stroke Teams enroll first patient in clinical trial of Penumbra System with Pulse flow restoration device

The Stroke Teams at the University Hospital Dresden in Dresden, Germany, and the University Hospital Göttingen in Göttingen, Germany, have enrolled the first patients in an international clinical trial to assess the safety and effectiveness of aspiration with the Penumbra System in conjunction with the Pulse flow restoration device.

2 Nov 2010

PITs compounds induce cell death and limit tumor growth

A class of compounds that interferes with cell signaling pathways may provide a new approach to cancer treatment, according to a study published online this week in the Proceedings of the National Academy of Sciences (PNAS) Early Edition. The compounds, called PITs (non-phosphoinositide PIP3 inhibitors), limited tumor growth in mice by inducing cell death.

2 Nov 2010

Oxygen Biotherapeutics receives $245,000 grant under PPACA 2010

Oxygen Biotherapeutics, Inc. today announced it has received nearly $245,000 in a grant under the Patient Protection and Affordable Care Program Act of 2010 (PPACA).

2 Nov 2010

Eli Lilly's new research center to focus on diabetes in China

Eli Lilly and Company announced today plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions.

2 Nov 2010

Teva third quarter net sales increase 20% to $4.3 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2010.

2 Nov 2010

New REACT medical trial for early diagnosis of lung cancer

Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.

2 Nov 2010

FDA announces partnership agreement with University of Rochester to form ACTION Initiative

The U.S. Food and Drug Administration today announced a partnership agreement with the University of Rochester to form the Analgesic Clinical Trial Innovations, Opportunities, and Networks (ACTION) Initiative.

2 Nov 2010

Einstein College's new website features latest information on aging research

Albert Einstein College of Medicine of Yeshiva University has launched SuperAgers.com, a new website that features the latest information on more than a decade of aging research at Einstein.

2 Nov 2010

Research on AID enzyme could improve therapy for lymphoma, leukemia

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

2 Nov 2010